23.14
2.25%
+0.51
After Hours:
23.14
Atricure Inc stock is currently priced at $23.14, with a 24-hour trading volume of 522.74K.
It has seen a +2.25% increased in the last 24 hours and a -1.32% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $22.43 pivot point. If it approaches the $23.54 resistance level, significant changes may occur.
Previous Close:
$22.63
Open:
$22.67
24h Volume:
522.74K
Market Cap:
$1.12B
Revenue:
$399.25M
Net Income/Loss:
$-30.44M
P/E Ratio:
-42.85
EPS:
-0.54
Net Cash Flow:
$-37.51M
1W Performance:
+3.77%
1M Performance:
-1.32%
6M Performance:
-44.24%
1Y Performance:
-52.41%
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 Innovation Way, Mason, OH
Atricure Inc Stock (ATRC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-18-20 | Reiterated | Needham | Buy |
Nov-06-20 | Reiterated | Needham | Buy |
Apr-07-20 | Initiated | Oppenheimer | Outperform |
Feb-06-20 | Initiated | BTIG Research | Buy |
Jan-24-20 | Reiterated | Needham | Buy |
Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
Apr-12-19 | Initiated | JP Morgan | Overweight |
Oct-04-18 | Reiterated | Needham | Buy |
Aug-02-18 | Reiterated | Needham | Buy |
Aug-02-18 | Reiterated | Stifel | Buy |
Jun-18-18 | Reiterated | Needham | Buy |
Apr-27-18 | Reiterated | Needham | Buy |
Jan-16-18 | Reiterated | Needham | Buy |
Nov-02-17 | Reiterated | Needham | Buy |
Jul-28-17 | Reiterated | Needham | Buy |
May-30-17 | Resumed | Piper Jaffray | Overweight |
Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
Oct-28-15 | Reiterated | Needham | Buy |
Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
AtriCure, Inc. (NASDAQ:ATRC) Short Interest Down 6.9% in April - MarketBeat
MarketBeat
AtriCure (ATRC): Moving Average Crossover Alert - Yahoo News UK
Yahoo News UK
AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference - Business Wire
Business Wire
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Singapore News
Yahoo Singapore News
AtriCure Enhances Governance and Expands Stock Plan - TipRanks.com - TipRanks
TipRanks
AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session - Yahoo Movies UK
Yahoo Movies UK
Atricure Inc Stock (ATRC) Financials Data
Atricure Inc (ATRC) Revenue 2024
ATRC reported a revenue (TTM) of $399.25 million for the quarter ending December 31, 2023, a +20.84% rise year-over-year.
Atricure Inc (ATRC) Net Income 2024
ATRC net income (TTM) was -$30.44 million for the quarter ending December 31, 2023, a +34.49% increase year-over-year.
Atricure Inc (ATRC) Cash Flow 2024
ATRC recorded a free cash flow (TTM) of -$37.51 million for the quarter ending December 31, 2023, a +3.86% increase year-over-year.
Atricure Inc (ATRC) Earnings per Share 2024
ATRC earnings per share (TTM) was -$0.66 for the quarter ending December 31, 2023, a +34.65% growth year-over-year.
About Atricure Inc
AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Cap:
|
Volume (24h):